|
Dezocine
|
Systematic (IUPAC) name
|
(5α,11α,13S)-13-amino-5,6,7,8,9,10,11,12-octahydro -5-methyl-5,11-methanobenzocyclodecen-3-ol
|
Identifiers
|
CAS number
| 53648-55-8
|
ATC code
| N02AX03
|
PubChem
| 40841
|
DrugBank
| APRD00912
|
Chemical data
|
Formula | C16H23NO
|
Mol. mass | 245.36 g/mol
|
Synonyms
| Dezocine, Dalgan
|
Pharmacokinetic data
|
Bioavailability | ?
|
Metabolism | Hepatic
|
Half life | 2.2 hours
|
Excretion | ?
|
Therapeutic considerations
|
Pregnancy cat.
|
?
|
Legal status
|
|
Routes
| intramuscular injection
|
Dezocine (Dalgan, WY-16225) is an opioid analgesic related to pentazocine, with a similar profile of effects that include analgesic action and euphoria at low doses,[1] but produces dysphoria and hallucinations at high doses, most likely due to action at κ-opioid receptors.[2][3]
Additional recommended knowledge
Dezocine has been found to be an effective painkiller comparable to meperidine (pethidine),[4] and so is a more effective analgesic than pentazocine, but causes relatively more respiratory depression than pentazocine.[5] It is a useful drug for the treatment of pain,[6] but side effects such as dizziness limit its clinical application,[7] and it can produce opioid withdrawal syndrome in patients already dependent on other opioids.[8]
Dezocine is unusual among opioids as it is the only primary amine known to be an active opioid. It is a mixed agonist-antagonist as with other drugs in this class,[9] and despite having a stronger respiratory depressant effect than morphine, dezocine shows a ceiling effect on its respiratory depressive action so above a certain dose this effect does not get any more severe.[10]
References
- ^ Zacny JP, Lichtor JL, de Wit H. Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers. Anesthesia and Analgesia. 1992 Apr;74(4):523-30.
- ^ Jacobs AM, Youngblood F. Opioid receptor affinity for agonist-antagonist analgesics. Journal of the American Podiatric Medical Association. 1992 Oct;82(10):520-4.
- ^ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacology. 2006 Jan 25;6:3.
- ^ Camu F, Gepts E. Analgesic properties of dezocine for relief of postoperative pain. Acta Anaesthesiologica Belgica. 1979;30 Suppl:183-91.
- ^ Wuest HP, Bellville JW. The respiratory effects of dezocine and pentazocine in man. Journal of Clinical Pharmacology. 1979 Apr;19(4):205-10.
- ^ O'Brien JJ, Benfield P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Aug;38(2):226-48.
- ^ Oosterlinck W, Verbaeys A. Preliminary clinical experience with dezocine, a new potent analgesic. Current Medical Research and Opinion. 1980;6(7):472-4.
- ^ Strain EC, Preston KL, Liebson IA, Bigelow GE. Opioid antagonist effects of dezocine in opioid-dependent humans.
Clinical Pharmacology and Therapeutics. 1996 Aug;60(2):206-17.
- ^ Young AM, Stephens KR, Hein DW, Woods JH. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. Journal Pharmacology and Experimental Therapeutics. 1984 Apr;229(1):118-26.
- ^ Romagnoli A, Keats AS. Ceiling respiratory depression by dezocine. Clinical Pharmacology and Therapeutics. 1984 Mar;35(3):367-73.
Opioids |
---|
Opiate derivatives | |
---|
Morphinans | |
---|
Benzomorphans | |
---|
4-Phenylpiperidines | |
---|
Open Chain Opioids |
Amidones |
|
Methadols |
|
Moramides |
|
Thiambutenes |
|
Phenalkoxams |
|
Ampromides |
|
Others |
Lefetamine |
|
---|
Anilidopiperidines | |
---|
Oripavine derivatives | |
---|
Phenazepines | |
---|
Pirinitramides | |
---|
Benzimidazoles | |
---|
Others | |
---|
|